| Category | Details | Evidence |
|---|---|---|
| Gene / protein identity | **Human ERO1A**; protein names include **ERO1-like protein alpha**, **ERO1α**, **ERO1-L**, **ERO1L**; a broadly expressed mammalian ERO1 isoform distinct from the more tissue-restricted ERO1β. | (pqac-00000005, pqac-00000006, pqac-00000007) |
| Enzyme class / cofactor | **FAD-containing ER-resident thiol oxidoreductase**; UniProt assigns **EC 1.8.3.2**. Structurally contains an FAD-binding core, inner and outer active sites, and a protruding β-hairpin used for docking to PDI. | (pqac-00000005, pqac-00000006, pqac-00000009) |
| Subcellular localization | Primarily localized in the **endoplasmic reticulum lumen** where oxidative folding occurs; also enriched at **mitochondria-associated ER membranes (MAMs/ERMCs)**, linking ER redox control to Ca²⁺ transfer and mitochondrial metabolism. | (pqac-00000000, pqac-00000004, pqac-00000008) |
| Primary enzymatic function | Catalyzes **oxidative protein folding** by re-oxidizing **protein disulfide isomerase (PDI)**, enabling PDI to introduce disulfide bonds into nascent secretory and membrane proteins. ERO1A acts as an exchange center for disulfide bonds and electrons in the ER. | (pqac-00000001, pqac-00000005, pqac-00000009) |
| Catalyzed redox reaction | Electrons flow from reduced substrate proteins to **PDI**, then to **ERO1A**, then to **FAD**, and finally to **molecular oxygen (O₂)**, producing **H₂O₂**. Overall, ERO1 couples disulfide bond formation to oxygen reduction; reviews note roughly **1 molecule of H₂O₂ is generated per disulfide bond formed**. | (pqac-00000004, pqac-00000009, pqac-00000011) |
| Direct biochemical substrate(s) | The principal direct enzymatic substrate is **reduced PDI** (especially the **a′ domain** of PDI). ERO1A can also interact with other ER thiol isomerases, but evidence indicates strongest preference for PDI. | (pqac-00000006, pqac-00000009, pqac-00000011) |
| Substrate affinity / specificity | Reported binding affinity for **PDI: Kd = 1.7 μM**. Weaker affinities reported for other ER oxidoreductases: **ERp44 21 μM, ERp5 70 μM, ERp57 180 μM, ERp72 160 μM, ERp46 280 μM**, supporting preferential engagement with PDI. | (pqac-00000010) |
| Immediate reaction products | Produces **oxidized PDI** and **H₂O₂**; oxidized PDI then transfers disulfides to client polypeptides. FAD cycles through reduced/oxidized states during catalysis. | (pqac-00000004, pqac-00000009, pqac-00000011) |
| Contribution to cellular ROS | ERO1A-derived H₂O₂ has been estimated to account for about **25% of H₂O₂ produced during protein translation / induced cellular ROS** in relevant settings, making ERO1A a major ER-localized ROS source. | (pqac-00000003, pqac-00000004, pqac-00000007) |
| Protein clients with strong functional evidence | Specific protein clients whose maturation/folding is promoted by ERO1A include **VEGF-A**, **PD-L1**, and matrix-degrading proteins such as **MMPs**; inhibition or loss of ERO1A restrains oxidative folding/secretion of these pro-tumoral proteins. | (pqac-00000005, pqac-00000009) |
| Regulation by UPR / ER stress | Strongly linked to the **unfolded protein response (UPR)**. The **PERK–eIF2α–ATF4–CHOP** branch induces ERO1A transcription; CHOP-dependent ERO1A upregulation is a recurring mechanism in ER-stress adaptation and, when excessive, apoptosis-associated signaling. | (pqac-00000000, pqac-00000005, pqac-00000007) |
| Regulation by hypoxia | **Hypoxia / HIF-1α** upregulates ERO1A, especially in tumors. This supports oxidative folding under low-oxygen conditions and helps maintain secretion of angiogenic and immune-regulatory proteins in hypoxic microenvironments. | (pqac-00000006, pqac-00000008, pqac-00000009) |
| Intrinsic redox regulation | ERO1A activity is tightly controlled by **regulatory intramolecular disulfide bonds** and by feedback through PDI; active/inactive states involve conserved cysteine pairs and shuttle disulfides that prevent hyperoxidation of the ER. | (pqac-00000006, pqac-00000011) |
| Related compensatory pathways | In mammals, ERO1A function can be partly buffered by other ER oxidoreductases/peroxidases including **PRDX4/PrxIV**, **GPx7**, **GPx8**, and **VKOR**, explaining why ERO1 loss is less catastrophic than in yeast. | (pqac-00000004, pqac-00000005, pqac-00000010) |
| Calcium homeostasis role | Beyond oxidative folding, ERO1A modulates **ER Ca²⁺ release** through **IP3R** and **RyR** pathways, affecting cytosolic/mitochondrial Ca²⁺ transfer, mitochondrial bioenergetics, and stress-induced apoptosis. | (pqac-00000005, pqac-00000007, pqac-00000008) |
| Core biological processes | **Oxidative protein folding**, **ER proteostasis**, **maintenance of ER redox environment**, **UPR/ER-stress adaptation**, **ROS generation/signaling**, **calcium homeostasis**, and support of secretion/maturation of disulfide-rich secreted or membrane proteins. | (pqac-00000000, pqac-00000001, pqac-00000004) |
| Disease / clinical significance | Frequently **upregulated in many cancers** and associated with worse prognosis, tumor growth, angiogenesis, metastasis, immune evasion, and therapy resistance. ERO1A is increasingly viewed as a **therapeutic target** because tumors may depend on it more than normal tissues. | (pqac-00000000, pqac-00000004, pqac-00000008) |
| Therapeutic translation / current applications | Preclinical work supports targeting the **ERO1A–PDI redox interface**. Small-molecule inhibitors such as **EN460** and newer analogs have been explored; ERO1A inhibition can impair tumor features by reducing oxidative folding/secretion of **VEGF-A** and **PD-L1**. | (pqac-00000001, pqac-00000004) |


*Table: This table condenses the main verified functional properties of human ERO1A, including its enzymatic role, substrates, localization, pathways, and disease relevance. It is useful as a quick-reference annotation summary grounded in the cited evidence contexts.*